Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs
Executive Summary
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
| Table |
|---|
Advertisement
Related Content
Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight
FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint
Amgen gains early US win for BiTE antibody Blincyto
Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour
Pfizer granted accelerated OK for Xalkori in NSCLC ahead of schedule
Topics
- Therapy Areas
- Cancer
- Subjects
- Research and Development Strategies
- Innovation
- Platform Technologies
- Clinical Trials
- Companies
- Research & Development
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125375
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC125375
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.